U.S. Stem Cell is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's lead product candidate is MyoCell, an innovative clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, for the purpose of improving cardiac function in chronic heart failure patients.
Revenue (Q2, 2018)
Gross profit (Q2, 2018)
Gross profit margin (Q2, 2018), %
Net income (Q2, 2018)
EBIT (Q2, 2018)
U.S. Stem Cell has 1.8k Twitter Followers. The number of followers has decreased 0.1% month over month and increased 0.9% quarter over quarter
U.S. Stem Cell has 1.67k Facebook Likes. The number of likes has increased 5% month over month and increased 11.9% quarter over quarter